FDA Opens Treatment Shift
On September 4, 2026, the FDA gave accelerated approval to AstraZeneca's Etcamah, the generic name for camizestrant, for use in adult patients with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer. The drug is to be used in combination with a CDK4/6 inhibitor once an ESR1 mutation appears while a patient is receiving ongoing aromatase inhibitor therapy. Speaking about the decision, Acting FDA Commissioner Kyle Diamantas described it as providing patients with an extra tool for dealing with tumours that find ways to evade treatment, and the approval thus makes it possible to enter a new phase in the management of breast cancer relapse.
Resistance Gets Earlier Detection
ESR1 mutations arise as a means of acquired resistance when a tumour is subjected to aromatase inhibitor treatment. At the time of the first diagnosis of hormone receptor-positive metastatic breast cancer, less than 5% of patients are found to have this mutation, but that figure rises steeply as the disease advances and reaches almost 40% of patients.
What makes this approval special is that camizestrant can be initiated as soon as the mutation is detected in a standard blood test by means of circulating tumour DNA, rather than having to wait for a scan to show that the cancer has gotten worse. However, Angelo de Claro, director of the FDA's Oncology Centre of Excellence, described it as the first approval of this type to detect a resistance mutation so early, although he added that further evidence is still needed to establish any real clinical benefit.
Pharma Meets Precision Diagnostics
The figures underlying the approval are difficult to ignore. In the study that supported this decision, patients who switched to camizestrant together with a CDK4/6 inhibitor had a median progression-free survival of 16 months, compared with 9.2 months for those who remained on their aromatase inhibitor combination, more than twice as long.
Guardant360 CDx was given approval as the companion diagnostic responsible for identifying eligible patients, thus linking AstraZeneca's drug to a particular testing procedure. The prescribing information does include a boxed warning concerning irregular heart rhythm when the drug is used in combination with certain other medications, along with warnings about a slow heart rate and fetal risk, points that will be important when physicians and insurers consider adopting the drug.
Oncology Moves Toward Prediction
The approval, which was approved by the FDA's Oncologic Drugs Advisory Committee in April 2026, remains based on the accelerated pathway and therefore AstraZeneca will have to carry out confirmatory trials in order to demonstrate that acting on molecular signals indeed results in a real clinical benefit. Nevertheless, the implication is clear: blood-based detection can now lead to changes in treatment before any imaging reveals a problem, thereby altering the fundamental principle as to when intervention should start. In an industry that is increasingly centred on biomarkers and companion diagnostics, this event may be recalled not so much as the approval of a single drug but rather as an early indication of the direction in which cancer treatment decisions will be moving in the future.
Explore what AstraZeneca’s approval signals for the future of precision oncology.